Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.32
+0.04003.13%
Post-market: 1.340.0200+1.52%17:13 EDT
Volume:467.49K
Turnover:609.16K
Market Cap:66.98M
PE:-0.56
High:1.35
Open:1.25
Low:1.23
Close:1.28
Loading ...

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
10 Dec 2024

Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; Cabaletta Bio to Advance, Super Micro Computer to Decline

MT Newswires Live
·
02 Dec 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

GlobeNewswire
·
26 Nov 2024

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

GlobeNewswire
·
18 Nov 2024

Cabaletta Bio’s RESET Trial Shows Promising Results in Autoimmune Disease Treatment, Supporting Buy Rating

TIPRANKS
·
18 Nov 2024

Cabaletta Bio Is Maintained at Overweight by Wells Fargo

Dow Jones
·
16 Nov 2024

Cabaletta Bio price target lowered to $12 from $20 at Wells Fargo

TIPRANKS
·
15 Nov 2024

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
15 Nov 2024

Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)

TIPRANKS
·
15 Nov 2024

Cabaletta Bio’s Strategic Expansion and Clinical Advancements Earn Buy Rating

TIPRANKS
·
15 Nov 2024

Cabaletta Bio’s Promising Trial Results and Proactive Management Secure Buy Rating

TIPRANKS
·
15 Nov 2024

Cabaletta Bio Inc reports results for the quarter - Earnings Summary

Reuters
·
14 Nov 2024

Cabaletta Bio Q3 2024 GAAP EPS $(0.62) Misses $(0.59) Estimate, Cash, Cash Equivalents And Short-term Investments Of $183M As Of September 30, 2024, Expected To Support Operations Into The First Half Of 2026

Benzinga
·
14 Nov 2024

Cabaletta Bio: Cash, Cash Equivalents & Short-Term Investments Total $183.0 Mln as of Sept 30, Expected to Support Operations Into H12026

THOMSON REUTERS
·
14 Nov 2024

Cabaletta Bio Q3 Operating Expenses USD 33.046 Million

THOMSON REUTERS
·
14 Nov 2024

Cabaletta Bio Q3 Income From Operations USD -33.046 Million

THOMSON REUTERS
·
14 Nov 2024

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire
·
14 Nov 2024

Cabaletta Bio Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

GlobeNewswire
·
06 Nov 2024